Your CRO Partner for
Preclinical Pharmacology
and In Vivo Services
Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.
Efficacy Models
Indications Discovery
In Vivo Services
Expert Consulting
Specialized Animal Models
Drug Repositioning
Your CRO Partner For
In Vivo Pharmacology
Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.
Melior Drug Discovery Philosophy
Watch the video
In Vivo Efficacy
Indications Discovery
Specialized Animal Models
Drug Repositioning
Andrew Reaume, PhD, CEO Melior Discovery
Trusted by the Top Leaders in Pharmacology
Melior Discovery's founding mission is drug repositioning - that is finding new uses for existing drugs.
State-of-the-art Preclinical Pharmacology Support
– Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry
State-of-the-art Preclinical Pharmacology Support
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry
Phenotypic screening uncovers otherwise
unpredicted new uses for a drug
Learn about our in vivo services
contract research capabilities in most therapeutic areas.
Melior has pioneered a phenotypic
screening platform (theraTRACE® ) suited for in vivo services, drug repositioning, or for identifying novel indications from development-stage candidates.
Serving our community since 2005
Thousands of studies
Hundreds of compounds evaluated
Dozens of animal models of human disease
Our Drug Discovery Philosophy
Recent Studies using Phenotypic Screening
A High-Throughput Assay for the Pancreatic Islet Beta-Cell Potassium Channel: Use in the Pharmacological Characterization of Insulin Secretagogues Identified from Phenotypic Screening.
Song L, Barrett DG, Cox KL, Efanov AM, Syed SK, Tomandl D, Willard FS
Phenotypic screening is a neoclassical approach for drug discovery. We conducted phenotypic screening for insulin secret...
Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
Grzegorzewicz AE, Lelièvre J, Esquivias J, Angala B, Liu J, Lee RE, McNeil MR, Jackson M
Phenotypic screening of inhibitors of the essential Mycobacterium tuberculosis FAS-II dehydratase, HadAB, led to the ide...